Therapeutic Abortion. Therapeutic/Medical Abortion (termination of pregnancy)
Conditions
Interventions
Intervention 1: First intervention group (control):
Receiving 8 Misoprostol 100 mcg tablets as a single vaginal dose from Abureyhan drug manufacturing company, Iran. Intervention 2: Second interventio
Treatment - Drugs
First intervention group (control):
Receiving 8 Misoprostol 100 mcg tablets as a single vaginal dose from Abureyhan drug manufacturing company, Iran
Second intervention group (trial):
Receiving 4 Letrozole 2.5 mg tablets daily for 3 days (orally), from Abureyhan drug manufacturing company, Iran
Plus
Receiving 8 Misoprostol 100 mcg tablets as a
Sponsors
Investigator
Eligibility
Sex/Gender
Female
Age
18 Years to 34 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Pregnant women with 18 to 34 years of age with nonviable pregnancy under 12 weeks from the first day of last menstrual period. Exclusion criteria: History of systemic diseases or presence of acute conditions that require any urgent intervention and treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The interval between induction and abortion beginning and opening of cervical internal os. Timepoint: Until 24 hours after receiving Misoprostol, every 1 hour. Method of measurement: Physical examination.;The interval between induction and complete abortion. Timepoint: Until 24 hours after receiving Misoprostol, every 1 hour. Method of measurement: Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal problems (nausea or vomiting). Timepoint: From receiving Letrozole until 24 hours after receiving Misoprostol. Method of measurement: Objective. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Masoumeh Mohammadi
Kosar Obstetrics and Gynecology Hospital
Outcome results
None listed